✦ LIBER ✦

Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy

✍ Scribed by Daniel C. Cho; Thomas E. Hutson; Wolfram Samlowski; Peter Sportelli; Brad Somer; Paul Richards; Jeffrey A. Sosman; Igor Puzanov; M. Dror Michaelson; Keith T. Flaherty; Robert A. Figlin; Nicholas J. Vogelzang

Book ID: 112067241
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 201 KB
Volume: 118
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.27668

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Re: Two Phase 2 Trials of the Novel Akt

Re: Two Phase 2 Trials of the Novel Akt Inhibitor Perifosine in Patients with Advanced Renal Cell Carcinoma After Progression on Vascular Endothelial Growth Factor-Targeted Therapy

✍ Taneja, Samir S. 📂 Article 📅 2012 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 104 KB

83 International, expanded-access progra

83 International, expanded-access programme of everolimus in patients with metastatic renal cell carcinoma who progressed after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: Sub-analysis of European patients

✍ S. Bracarda; S. Rottey; A. Bahl; C. Eichelberg; B. Mellado; L. Mangel; J. Mardia 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 35 KB

An international expanded-access program

An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

✍ Viktor Grünwald; Pierre I. Karakiewicz; Sevil E. Bavbek; Kurt Miller; Jean-Pasca 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 257 KB

Everolimus in metastatic renal cell carc

Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study

✍ E. Calvo; B. Escudier; R.J. Motzer; S. Oudard; T.E. Hutson; C. Porta; S. Bracard 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 262 KB

Comparative efficacy of vascular endothe

Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI

✍ Kwonoh Park, Jae-Lyun Lee, Inkeun Park, Seongjoon Park, Yongcheol Ahn, Jin-Hee A 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 193 KB